Low MHPG and continuing treatment in panic disorder

Area of Science:

• Neuroscience
• Psychiatry
• Clinical Psychology

Background:

• Panic disorder is a debilitating condition impacting millions globally.
• Biomarkers for treatment response in panic disorder are actively sought.
• 3-Methoxy-4-hydroxyphenylglycol (MHPG) is a metabolite of norepinephrine, a neurotransmitter implicated in stress and mood regulation.

Purpose of the Study:

• To investigate the relationship between baseline MHPG levels and treatment response in panic disorder.
• To explore whether MHPG levels predict treatment adherence and clinical improvement.

Main Methods:

• A naturalistic study involving 28 unmedicated panic disorder patients.
• MHPG levels were measured at baseline and follow-up (average 6.8 months).
• Patients had the option to continue or discontinue treatment; clinical outcomes were assessed using panic attack frequency, Zung Anxiety Scale, and Beck/Hamilton Depression Scales.

Main Results:

• Patients who continued treatment exhibited significantly lower baseline MHPG levels compared to those who discontinued.
• No significant baseline differences in panic attacks or anxiety/depression scores were observed between the groups.
• Patients continuing treatment showed significant improvement across all clinical measures at follow-up.

Conclusions:

• Lower MHPG levels may be associated with greater persistence in seeking treatment for panic disorder.
• Reduced MHPG could potentially serve as a predictor of positive treatment response in panic disorder.
• Further research is warranted to elucidate the role of MHPG in panic disorder pathophysiology and treatment.